ONCOLOGY Nurse Edition April 2008, Vol 22 No 4

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Tislelizumab plus chemotherapy demonstrated superior OS, PFS, ORR, and DOR results compared with placebo plus chemotherapy in first-line ES-SCLC.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

Talquetamab Elicits Sustained Responses in Pre-Treated R/R Multiple Myeloma

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

$Cytokine release syndrome events primarily occurred during step-up and the first full dosing cycle in patients with relapsed/refractory multiple myeloma.$

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

Cytokine release syndrome events primarily occurred during step-up and the first full dosing cycle in patients with relapsed/refractory multiple myeloma.

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Leticia Nogueira, PhD, MPH

HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

PIPAC-MMC Plus FOLFIRI Shows Feasibility, Safety in Peritoneal Metastases

Muhammed Talha Waheed, MD, stated that a retrospective study found an OS benefit in CRC peritoneal metastasis with cytoreduction surgery without HIPEC vs with HIPEC.

Laparoscopic, histologic, and biomarker responses occurred at all dose levels of mitomycin treatment in patients with peritoneal metastases.

CHMP Grants Positive Opinion to Tislelizumab/Chemo in Front-Line ES-SCLC

Laparoscopic, histologic, and biomarker responses occurred at all dose levels of mitomycin treatment in patients with peritoneal metastases.

Related Content

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Tislelizumab plus chemotherapy demonstrated superior OS, PFS, ORR, and DOR results compared with placebo plus chemotherapy in first-line ES-SCLC.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

Talquetamab Elicits Sustained Responses in Pre-Treated R/R Multiple Myeloma

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

$Cytokine release syndrome events primarily occurred during step-up and the first full dosing cycle in patients with relapsed/refractory multiple myeloma.$

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

Cytokine release syndrome events primarily occurred during step-up and the first full dosing cycle in patients with relapsed/refractory multiple myeloma.

Leticia Nogueira, PhD, MPH

HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

PIPAC-MMC Plus FOLFIRI Shows Feasibility, Safety in Peritoneal Metastases

Muhammed Talha Waheed, MD, stated that a retrospective study found an OS benefit in CRC peritoneal metastasis with cytoreduction surgery without HIPEC vs with HIPEC.